Cellworks Study Predicted Non-Response to Azacitidine in MDS Patients with 100% Accuracy using AI-Driven Biosimulation
Analysis Uncovered Possible Mechanisms for AZA Resistance that could be Targeted to…
Cellworks AI-Driven Biosimulation Predicted Chemo-resistance in AML and MDS Patients with 90% Accuracy
Prospective Study Successfully Identified Mechanisms for AML…
Cellworks to Present 10 Abstracts at 2018 American Society of Hematology Annual Meeting
ASH Abstracts Reveal How AI-Driven Biosimulation Technology Predicts Drug Response in…
Former UnitedHealth Group Cancer Director Dr. Lee Newcomer Joins Cellworks Board of Directors
Leading Precision Medicine Company Adds to Prestigious Board of Directors, which…
Dr. Allen Lichter Joins Cellworks Group Board of Directors
Former CEO of ASCO Elected to Board of Leading Precision Medicine Company
…
Tackling the TB epidemic
LONDON—As tuberculosis drug sensitivity and resistance reaches epidemic proportions in…
Wellcome Trust supports collaboration to find new treatment for tuberculosis
The Wellcome Trust has supported a collaboration between AstraZeneca and Cellworks to…
AstraZeneca And Cellworks Collaborate To Find New Treatment For Tuberculosis
AstraZeneca and Cellworks today announced a collaboration supported by the Wellcome…
Predicting Pathway Effects
Drug development programs today have a 5% to 10% probability of success. Almost half…
Innovate while derisking drug development- yes we can!
The outlook for the drug industry continues to remain bleak in context of productivity…
Cellworks Taps Semiconductor Expertise to Boost Predictability
With $7.5 million of Series A funding in hand and a Series B round on deck, Cellworks…
Going for multiple shots on goal
As the first part of this series began with the single word, "Viagra," this…
